Teva Pharmaceutical Industries (TEVA) Common Equity (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Common Equity across 18 years of filings, most recently posting $8.2 billion for Q1 2026.

• Quarterly Common Equity rose 31.31% year-over-year to $8.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 billion (up 31.31% YoY) and the FY2025 annual result came in at $7.9 billion, up 47.1% from the prior year.
• Common Equity grew to $8.2 billion in Q1 2026, from $7.9 billion in the prior quarter.
• Over five years, Common Equity peaked at $10.3 billion in Q1 2022 and troughed at $5.4 billion in Q4 2024.
• A 5-year average of $7.8 billion and a median of $7.6 billion in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity plunged 33.79% — and 2025, when it surged 47.1%.
• Tracing TEVA's Common Equity over 5 years: stood at $8.6 billion in 2022, then dropped by 5.49% to $8.1 billion in 2023, then tumbled by 33.79% to $5.4 billion in 2024, then surged by 47.1% to $7.9 billion in 2025, then gained by 4.02% to $8.2 billion in 2026.
• Business Quant data shows TEVA's Common Equity at $8.2 billion in Q1 2026, $7.9 billion in Q4 2025, and $7.3 billion in Q3 2025.